

Notice of Allowability	Application No.	Applicant(s)
	10/811,198	COMMUNI ET AL.
	Examiner	Art Unit
	Ruixiang Li	1646

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to Applicants' amendment filed on 06/29/2007.
2. The allowed claim(s) is/are 1, 4-7, which will be issued as claims 1-5, respectively.
3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All
 - b) Some*
 - c) None
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. 09/077,173.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No./Mail Date _____.
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)
2. Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date _____
4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. Notice of Informal Patent Application
6. Interview Summary (PTO-413),
Paper No./Mail Date _____
7. Examiner's Amendment/Comment
8. Examiner's Statement of Reasons for Allowance
9. Other _____.

Ruixiang Li.

RUIXIANG LI, PH.D.
PRIMARY EXAMINER

EXAMINER'S AMENDMENT/COMMENT

Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee. Authorization for this examiner's amendment was given in a telephone interview with Amy DeCloux August 16, 2007.

Amendment to Claims

(i). Cancel claims 2, 3, and 8-23.

(ii). claim 6 has been replaced by the following:

6. A composition comprising the antibody of claim 1, and a carrier.

(ii). In claim 7, line 1, delete "pharmaceutical".

Amendment to Specification

(i) Amendment to the first paragraph of Specification

After "This application is a divisional of Application Serial No. 10/753, 695, filed January 8, 2004, which is a divisional of Application Serial No. 09/077,173, filed on Nov 12, 1998", insert --issued as US Patent No. 6,790,626 --.

(ii). On page 9, line 21, after "FIG. 1", insert --represents the nucleotide and deduced amino acid sequence of a human P2Y₄ receptor according to the invention, SEQ ID NO: 1 and SEQ ID NO: 2, respectively. --.

(iii). On page 14, line 23, after the nucleotide sequence, insert --(SEQ ID NO: 3) --.

(iv). On page 14, line 25, after the nucleotide sequence, insert --(SEQ ID NO: 4) --.

Amendment to Title

Applicants are also advised that the title has been changed to more accurately reflect the claimed invention. The title now reads:

"P2Y4 antibodies".

Conclusion

Claims 1 and 4-7 are allowed. Claims 1 and 4-7 will be issued as claims 1-5, respectively.

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ruixiang Li whose telephone number is (571) 272-0875. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00

Art Unit: 1646

pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol, can be reached on (571) 272-0835. The fax number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, please contact the Electronic Business Center (EBC) at the toll-free phone number 866-217-9197.

Ruixiang Li

Ruixiang Li, Ph.D.
Primary Examiner
August 16, 2007

RUIXIANG LI, PH.D.
PRIMARY EXAMINER